Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

London Drugs stores in Metro Vancouver now have the ability for transit users to purchase and load their new Compass Cards. The 18 locations were selected based on proximity to transit stations and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could help speed access to its experimental psilocybin therapy, which the company ...

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for ...

Compass Pathways Plc., a U.K. startup backed by tech billionaire Peter Thiel and lead investor Christian Angermayer, has filed to go public about four years after it was founded to explore the use of ...

Compass Pathways CMPS, a company developing psychedelic pharmaceutical drugs for the mental health space, announced the publication of two new investigator-initiated studies using its flagship ...

The stock dropped, despite fairly positive data. Investors are worried about long-term efficacy. There's also concern about side effects, although that may be tied to the disease rather than the drug.

Compass Pathways (CMPS) added ~20% in the premarket on Tuesday after the U.K.-based biotech announced that its psychedelic therapy COMP360 reached the primary endpoint in a late-stage trial for ...

Compass Pathways has filed paperwork for a Nasdaq IPO that will tee it up to take psilocybin therapy COMP360 through midphase development. Compass is developing psilocybin, the active ingredient in ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara ®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that the entire ...